The Marker State Space (MSS) Method for Classifying Clinical Samples

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Fallon, Brian P ^a   Curnutte, Bryan ^a   Maupin, Kevin A ^a   Partyka, Katie ^a   Choi, Sunguk ^b   Brand, Randall E ^c   Langmead, Christopher J ^b   Tembe, Waibhav ^d   Haab, Brian B ^a  

^a VAN ANDEL INSTITUTE   (United States)

^b CARNEGIE MELLON UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ACCURACY; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CLASSIFICATION ALGORITHM; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MARKER STATE SPACE; MICROARRAY ANALYSIS; PANCREAS CANCER; PANCREATITIS; PATIENT CODING; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; DIAGNOSIS, DIFFERENTIAL; HUMANS; PANCREATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SOFTWARE;

EID: 84878655735     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065905     Document Type: Article

References (37)

1. Ludwig JA, Weinstein JN, (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5: 845-856.
2. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, et al. (2003) The case for early detection. Nat Rev Cancer 3: 243-252.
3. Hoggatt J, (2011) Personalized medicine-trends in molecular diagnostics: exponential growth expected in the next ten years. Mol Diagn Ther 15: 53-55.
4. La Thangue NB, Kerr DJ, (2011) Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 8: 587-596.
5. Lukes M, Urban M, Zalesky M, Zachoval R, Heracek J, et al. (2001) Prostate-specific antigen: current status. Gynecol Oncol 47: 41-49.
6. Alonzo TA, Pepe MS, (2007) Development and evaluation of classifiers. Methods Mol Biol 404: 89-116.
7. Baek S, Tsai CA, Chen JJ, (2009) Development of biomarker classifiers from high-dimensional data. Brief Bioinform 10: 537-546.
8. Koziol JA, Zhang JY, Casiano CA, Peng XX, Shi FD, et al. (2003) Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 9: 5120-5126.
9. Lombardi C, Tassi GF, Pizzocolo G, Donato F, (1990) Clinical significance of a multiple biomarker assay in patients with lung cancer. A study with logistic regression analysis. Chest 97: 639-644.
10. Gail MH, Muenz L, McIntire KR, Radovich B, Braunstein G, et al. (1988) Multiple markers for lung cancer diagnosis: validation of models for localized lung cancer. J Natl Cancer Inst 80: 97-101.
11. Bouwman K, Qiu J, Zhou H, Schotanus M, Mangold LA, et al. (2003) Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics 3: 2200-2207.
12. Dudoit S, Fridlyand J, Speed TP, (2002) Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data. Journal of the American Statistical Association 97: 77-87.
13. Zhang H, Yu CY, Singer B, (2003) Cell and tumor classification using gene expression data: construction of forests. Proc Natl Acad Sci U S A 100: 4168-4172.
14. Breiman L, (1996) Bagging predictors. Machine Learning 24: 123-140.
15. Dillman RO, Koziol JA, (1983) Statistical approach to immunosuppression classification using lymphocyte surface markers and functional assays. Cancer Res 43: 417-421.
16. Cook EF, Goldman L, (1984) Empiric comparison of multivariate analytic techniques: advantages and disadvantages of recursive partitioning analysis. J Chronic Dis 37: 721-731.
17. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
18. Prat A, Perou CM, (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5: 5-23.
19. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, et al. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8: 393-406.
20. Kloppel G, Adsay NV, (2009) Chronic pancreatitis and the differential diagnosis versus pancreatic cancer. Arch Pathol Lab Med 133: 382-387.
21. Chen S, LaRoche T, Hamelinck D, Bergsma D, Brenner D, et al. (2007) Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods 4: 437-444.
22. Yue T, Goldstein IJ, Hollingsworth MA, Kaul K, Brand RE, et al. (2009) The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics 8: 1697-1707.
23. Chen S, Haab BB (2007) Antibody Microarrays for Protein and Glycan Detection. In: Van Eyk J, Dunn M, editors. Clinical Proteomics. Weinheim, Germany: Wiley, VCH.
24. Haab BB, (2010) Antibody-lectin sandwich arrays for biomarker and glycobiology studies. Expert Rev Proteomics 7: 9-11.
25. Bergsma D, Buchweitz J, Chen S, Gerszten R, Haab B, (2010) Antibody-array interaction mapping (AAIM): A new method to detect protein complexes applied to the discovery and study of serum amyloid P interactions with kininogen in human plasma. Molecular Cellular Proteomics 9: 446-456.
26. Orchekowski R, Hamelinck D, Li L, Gliwa E, vanBrocklin M, et al. (2005) Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res 65: 11193-11202.
27. Haab BB, Porter A, Yue T, Li L, Scheiman J, et al. (2010) Glycosylation Variants of Mucins and CEACAMs as Candidate Biomarkers for the Diagnosis of Pancreatic Cystic Neoplasms. Annals of Surgery 251: 937-945.
28. Maupin K, Sinha A, Eugster E, Miller J, Ross J, et al. (2010) Glycogene Expression Alterations Associated with Pancreatic Cancer Epithelial-Mesenchymal Transition in Complementary Model Systems. PLoS ONE 5: e13002.
29. Wu YM, Nowack DD, Omenn GS, Haab BB, (2009) Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J Proteome Res 8: 1876-1886.
30. Yue T, Maupin KA, Fallon B, Li L, Partyka K, et al. (2011) Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS ONE 6: e29180.
31. Yue T, Partyka K, Maupin KA, Hurley M, Andrews P, et al. (2011) Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics 11: 3665-3674.
32. Partyka K, Maupin KA, Brand RE, Haab BB, (2012) Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation. Proteomics 12: 2212-2220.
33. Goonetilleke KS, Siriwardena AK, (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33: 266-270.
34. Manimala JC, Roach TA, Li Z, Gildersleeve JC, (2007) High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology 17: 17C-23C.
35. Porter A, Yue T, Heeringa L, Day S, Suh E, et al. (2010) A motif-based analysis of glycan array data to determine the specificities of glycan-binding proteins. Glycobiology 20: 369-380.
36. Hakomori S, (1999) Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta 1473: 247-266.
37. Wang CY, Feng Z, (2010) Boosting with missing predictors. Biostatistics 11: 195-212.